Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
about
Non-invasive diagnostic imaging of colorectal liver metastasesFocal liver lesions: Practical magnetic resonance imaging approachClinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumorPrognostication and response assessment in liver and pancreatic tumors: The new imagingMetabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentialityImaging in Colorectal Cancer: Progress and Challenges for the CliniciansPrognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysisPractical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretationEvaluation of the effect of transcytolemmal water exchange analysis for therapeutic response assessment using DCE-MRI: a comparison studyDevelopment of a temperature-controlled phantom for magnetic resonance quality assurance of diffusion, dynamic, and relaxometry measurements.Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysisPET scans as a predictive marker of survival in advanced colorectal cancer.Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer.Update on the role of imaging in management of metastatic colorectal cancerRegional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot studyEarly 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.Dynamic fractal signature dissimilarity analysis for therapeutic response assessment using dynamic contrast-enhanced MRI.Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma.Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial.Usefulness of dynamic contrast-enhanced magnetic resonance imaging for predicting treatment response to vinorelbine-cisplatin with or without recombinant human endostatin in bone metastasis of non-small cell lung cancer.Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.The role of functional imaging in the era of targeted therapy of renal cell carcinoma.Intravoxel incoherent motion (IVIM) MR imaging of colorectal liver metastases: are we only looking at tumor necrosis?Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update.Prognostic value of positron emission tomography/computed tomography for adjuvant chemotherapy of colon cancer.Multi-modal magnetic resonance imaging and histology of vascular function in xenografts using macromolecular contrast agent hyperbranched polyglycerol (HPG-GdF).Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy.Radiofrequency Ablation to Improve Survival After Conversion Chemotherapy for Colorectal Liver Metastases.Assessment of therapeutic response in Crohn's disease using quantitative dynamic contrast enhanced MRI (DCE-MRI) parameters: A preliminary study.Multimodality Imaging in Tumor Angiogenesis: Present Status and PerspectivesThe value of DCE-MRI in assessing histopathological and molecular biological features in induced rat epithelial ovarian carcinomas.Magnetic resonance perfusion characteristics of hypervascular renal and hypovascular prostate spinal metastases: clinical utilities and implications.Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab.Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.Dynamic contrast-enhanced MRI to evaluate the therapeutic response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.Potential of MR histogram analyses for prediction of response to chemotherapy in patients with colorectal hepatic metastases.Late gadolinium enhancement of colorectal liver metastases post-chemotherapy is associated with tumour fibrosis and overall survival post-hepatectomyNoninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives
P2860
Q26798428-D64B4041-F665-4B5C-8DE2-86FC0C488FF6Q26799474-410ED65B-B7CB-45FC-9BA5-C1C9E979E8E7Q27005824-BABE2EEB-5587-4C2C-B35A-C350970B7A2CQ27021568-82A04528-8D53-4BB7-BADA-C0066AE05B77Q27025007-14762CB3-BA24-48C2-A0E4-4CC5DA2CD45DQ28067562-26CC8173-1F9B-43C2-AD84-55E9A9B4DDD9Q28081159-A3FC93D4-8ADA-4FD9-AA6C-F4D5FCB3A54DQ30575110-5CBF71AA-78E2-4741-AC7A-E84AB0CBF612Q31106171-78688B82-F62D-4279-951F-A39D0C900D15Q31106559-4B9F77FB-2806-476C-8450-02C20A75734CQ33926377-2A7565CF-3970-4290-8457-B0A78EE3C356Q35128437-634DDB42-9CE3-4CB8-920E-33E8A79B4E42Q35242758-FBCB8358-07E8-4F7E-9FC9-89AEE40DFD60Q35285305-61B4C7C7-A253-434F-98EF-59DD16A98ED2Q35892542-10C52CC2-F23D-4B0C-A8A8-D3EB14091102Q35929346-41F6B16E-0AED-4121-9B8C-08DBFB112C33Q36022493-24B95C0C-29EC-43C4-9DAB-2411277C12E7Q36599503-5AD5149B-E064-483E-B399-807AC9C9D1E0Q36747536-521F15BD-D3A1-4E32-BE1C-CBFF83B4EF04Q37367448-AFFBDBD7-0025-43CB-A5BE-185D9C2D5134Q37545124-8774BD0F-EF5C-4703-96D4-0CF7BF73F3B5Q37589065-28E8AE88-A5FB-4989-AC01-3E72B124ED89Q38099238-E34D187D-E5FE-498E-B2C0-CBD6EDC4067BQ38110741-CC012E8D-8AE2-4983-8A40-2571340C267DQ38317180-564FC975-4EAE-4D32-BCE0-5A28AE57018BQ38689156-4205F568-55A0-4E9F-83E7-AFD218258D4CQ38844101-456D875A-D0C6-402E-A57E-A368A864B685Q39416640-349D6460-0C02-454A-9F78-2BE7CD73B25FQ40738190-C550D592-1908-4FD5-AE25-D148E7D0ED0BQ41390534-4917B2E0-CB48-4949-ADC3-637BEE54A74AQ41661199-EC151FE1-A075-4351-AF5F-BAB62681492FQ41675215-10F2F2F0-6772-4092-BA9B-E706115A1CACQ41753753-0D8294B5-BB15-4694-BF58-437C8C33E11BQ42181722-646AF6AF-1089-40C5-BDBD-B3E4F9B04D5FQ42642023-5FAB364F-5984-493E-93F9-AEDB5F7FA545Q44279936-CDA1C827-4AB2-44C1-9284-D890554AEC89Q48541561-F920DB53-93B2-46D9-8241-60B049A1FF38Q53302447-38C1BD2E-70A4-4F5C-835E-09B71085C1CFQ56524446-AFE31036-56A1-48D2-AA1B-7038954D5F02Q57739115-9FCB50BD-A0C6-4996-B6EF-7331917AAF85
P2860
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Value of DCE-MRI and FDG-PET/C ...... r colorectal liver metastases.
@ast
Value of DCE-MRI and FDG-PET/C ...... r colorectal liver metastases.
@en
type
label
Value of DCE-MRI and FDG-PET/C ...... r colorectal liver metastases.
@ast
Value of DCE-MRI and FDG-PET/C ...... r colorectal liver metastases.
@en
prefLabel
Value of DCE-MRI and FDG-PET/C ...... r colorectal liver metastases.
@ast
Value of DCE-MRI and FDG-PET/C ...... r colorectal liver metastases.
@en
P2093
P2860
P356
P1476
Value of DCE-MRI and FDG-PET/C ...... r colorectal liver metastases.
@en
P2093
C Van de Wiele
L Ferdinande
L Libbrecht
N Van Damme
S De Bruyne
P2860
P2888
P304
P356
10.1038/BJC.2012.184
P407
P50
P577
2012-05-17T00:00:00Z
P5875
P6179
1026913145